Download PDF
Thromb Haemost 2019; 119(07): 1112-1123
DOI: 10.1055/s-0039-1688787
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response

Abdullah Hamadi
1   Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
,
Andrew P. Grigg
2   Department of Clinical Haematology, Austin Hospital, Heidelberg, Victoria, Australia
,
Gasim Dobie
1   Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
,
Kate L. Burbury
3   Department of Haematology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
,
Anthony P. Schwarer
4   Department of Haematology, Eastern Health, Box Hill, Victoria, Australia
,
Faith A. Kwa
1   Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
,
Denise E. Jackson
1   Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
› Author Affiliations Funding This work was supported by funding from Ariad/Takada (Boston, United States) (D.E. Jackson and K. Burbury). Abdullah Hamadi was supported by a postgraduate scholarship from Tabuk University and Ministry of Higher Education (Riyadh, Saudi Arabia).
Further Information

Publication History

11 December 2018

20 March 2019

Publication Date:
12 May 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Both nilotinib, a second-generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukaemia (CML), and ponatinib, a third-generation TKI used in CML and Philadelphia positive acute lymphocytic leukaemia, have been associated with an increase in arterial occlusive events, in contrast to other TKIs such as imatinib and dasatinib. We have previously demonstrated evidence of a pro-thrombotic state associated with nilotinib, using microvascular and arterial thrombosis C57BL/6 mouse models. In this study, we examined ponatinib and determined if a calcium channel blocker could ameliorate the pro-thrombotic and pro-inflammatory phenotypes. In vitro treatment of whole human or murine blood with ponatinib and nilotinib increased platelet activation, adhesion and three-dimensional thrombi over time compared with vehicle control or other TKIs. Treatment of wild-type C57BL/6 mice with ponatinib and nilotinib but not imatinib, dasatinib or vehicle control for 4 hours significantly increased thrombus growth following ex vivo perfusion on collagen and FeCl3-induced vascular injury of mesenteric arterioles and carotid artery in vivo and increased plasma levels of soluble P-selectin, tumour necrosis factor-α, interleukin-6, interferon-γ and thromboxane B2 (TxB2). Ponatinib-treated CML patients had increased ex vivo thrombus formation and a pro-inflammatory phenotype compared with healthy controls. Pre-treatment of mice with the calcium channel antagonist, diltiazem, prior to ponatinib or nilotinib reversed the pro-thrombotic phenotype and the increase in cytokine levels. These observations suggest that the pro-thrombotic effect of nilotinib and ponatinib is partially related to calcium channel activation and TxA2 generation and this should be explored clinically as a mechanism to prevent vascular events.

Keywords

calcium channel blocker - nilotinib - ponatinib - pro-thrombotic - tyrosine kinase inhibitor - thromboxane A2

Authors' Contributions

A.H. performed experiments. F.K., K.B. and A.G. provided intellectual input and review of the article. D.E.J. directed the research and wrote the manuscript.


 

  • References

  • 1 Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112 (13) 4808-4817
    CrossrefPubMedSearch in Google Scholar
  • 2 Falchi L, Kantarjian HM, Wang X. , et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013; 88 (12) 1024-1029
    CrossrefPubMedSearch in Google Scholar
  • 3 Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 2013; 4 (02) 103-117
    CrossrefPubMedSearch in Google Scholar
  • 4 O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110 (07) 2242-2249
    CrossrefPubMedSearch in Google Scholar
  • 5 Huang W-S, Metcalf CA, Sundaramoorthi R. , et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenylbenzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010; 53 (12) 4701-4719
    CrossrefPubMedSearch in Google Scholar
  • 6 Zhou T, Commodore L, Huang W-S. , et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77 (01) 1-11
    CrossrefPubMedSearch in Google Scholar
  • 7 Cortes JE, Kantarjian H, Shah NP. , et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367 (22) 2075-2088
    CrossrefPubMedSearch in Google Scholar
  • 8 Cortes JE, Kim DW, Pinilla-Ibarz J. , et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369 (19) 1783-1796
    CrossrefPubMedSearch in Google Scholar
  • 9 Cortes JE, Kim DW, Pinilla-Ibarz J. , et al. Ponatinib, efficacy and safety in heavily pretreated leukaemia patients: 3-year results of the PACE trial. Haematologica 2015; 100 (Suppl. 01) 64
    PubMedSearch in Google Scholar
  • 10 Food and Drug administration. FDA news release: FDA approves Iclusig to treat two rare types of leukaemia. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm . Accessed December 13, 2012
    PubMed
  • 11 Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015; 125 (06) 901-906
    CrossrefPubMedSearch in Google Scholar
  • 12 Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12 (05) 337-340
    CrossrefPubMedSearch in Google Scholar
  • 13 Pasvolsky O, Leader A, Iakobishvili Z. , et al. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardiooncology 2015; 1: 5-15
    PubMedSearch in Google Scholar
  • 14 Kirsch A, Kirchmair R, Frank S. Ponatinib augments vasoconstriction and attenuates vasorelaxation in mouse aortic rings. Atherosclerosis 2016; 252: e221
    PubMedSearch in Google Scholar
  • 15 Kadzijusufovic E, Kirchmair R, Theurl M. , et al. Ponatinib exert multiple effects on vascular endothelial cells: possible mechanisms and explanations for the adverse vascular events seen in CML patients treated with ponatinib. Blood 2016; 128: 1883
    CrossrefPubMedSearch in Google Scholar
  • 16 Yan ZX, Luo Y, Liu NF. Blockade of angiopoietin-2/Tie2 signaling pathway specifically promotes inflammation-induced angiogenesis in mouse cornea. Int J Ophthalmol 2017; 10 (08) 1187-1194
    PubMedSearch in Google Scholar
  • 17 Alhawiti N, Burbury KL, Kwa FA. , et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res 2016; 145: 54-64
    CrossrefPubMedSearch in Google Scholar
  • 18 Alshahrani MM, Yang E, Yip J. , et al. CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo. Blood 2014; 124 (15) 2431-2441
    PubMedSearch in Google Scholar
  • 19 Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 2011; 9 (Suppl. 01) 92-104
    PubMedSearch in Google Scholar
  • 20 Schmaier AH, Merkulova AA, Mitchell S. , et al. Ponatinib and cardiovascular complications. Blood 2016; 128: 3055
    CrossrefPubMedSearch in Google Scholar
  • 21 Ferroni P, Martini F, Riondino S. , et al. Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta 2009; 399 (1-2): 88-91
    CrossrefPubMedSearch in Google Scholar
  • 22 Semenov AV, Romanov YA, Loktionova SA. , et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc) 1999; 64 (11) 1326-1335
    PubMedSearch in Google Scholar
  • 23 Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003; 101 (07) 2661-2666
    CrossrefPubMedSearch in Google Scholar
  • 24 Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24 (24) 2166-2179
    CrossrefPubMedSearch in Google Scholar
  • 25 Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, Koksch M. P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 2000; 11 (08) 723-728
    CrossrefPubMedSearch in Google Scholar
  • 26 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103 (04) 491-495
    CrossrefPubMedSearch in Google Scholar
  • 27 Woollard KJ, Kling D, Kulkarni S, Dart AM, Jackson S, Chin-Dusting J. Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ Res 2006; 98 (01) 149-156
    CrossrefPubMedSearch in Google Scholar
  • 28 Gora-Tybor J, Medras E, Calbecka M. , et al. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma 2015; 56 (08) 2309-2314
    CrossrefPubMedSearch in Google Scholar
  • 29 Fiets RB, Staal AHJ, Cramer GE, Blijlevens NMA. Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia. Neth J Med 2018; 76 (07) 330-335
    PubMedSearch in Google Scholar
  • 30 Massie BM, Hirsch AT, Inouye IK, Tubau JF. Calcium channel blockers as antihypertensive agents. Am J Med 1984; 77 (4A): 135-142
    PubMedSearch in Google Scholar
  • 31 Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther 2000; 292 (02) 606-609
    PubMedSearch in Google Scholar
  • 32 Peng B, Hayes M, Resta D. , et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22 (05) 935-942
    CrossrefPubMedSearch in Google Scholar
  • 33 Kantarjian H, Giles F, Wunderle L. , et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354 (24) 2542-2551
    CrossrefPubMedSearch in Google Scholar
  • 34 Araujo JC, Mathew P, Armstrong AJ. , et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012; 118 (01) 63-71
    CrossrefPubMedSearch in Google Scholar
  • 35 Lipton JH, Chuah C, Guerci-Bresler A. , et al; EPIC investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17 (05) 612-621
    CrossrefPubMedSearch in Google Scholar
  • 36 Cortes JE, Kim DW, Pinilla-Ibarz J. , et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132 (04) 393-404 . Doi: 10.1182/blood-2016-09-739086
    PubMedSearch in Google Scholar
  • 37 Parker WT, Lawrence RM, Ho M. , et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol 2011; 29 (32) 4250-4259
    CrossrefPubMedSearch in Google Scholar